1. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Issue 10200 (31st August 2019) Authors: Croop, Robert; Goadsby, Peter J; Stock, David A; Conway, Charles M; Forshaw, Micaela; Stock, Elyse G; Coric, Vladimir; Lipton, Richard B Journal: Lancet Issue: Volume 394:Issue 10200(2019) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ‐secretase inhibitor avagacestat. (14th December 2012) Authors: Tong, Gary; Wang, Jun‐Sheng; Sverdlov, Oleksandr; Huang, Shu‐Pang; Slemmon, Randy; Croop, Robert; Castaneda, Lorna; Gu, Huidong; Wong, Oi; Li, Hewei; Berman, Robert M.; Smith, Christina; Albright, Charles F.; Dockens, Randy Journal: British journal of clinical pharmacology Issue: Volume 75:Number 1(2013:Jan.) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Testing rimegepant for migraine—time to revise the trial design? – Authors' reply. Issue 10241 (20th June 2020) Authors: Croop, Robert; Goadsby, Peter J; Stock, David A; Lipton, Richard B Journal: Lancet Issue: Volume 395:Issue 10241(2020) Page Start: 1901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. (19th May 2020) Authors: Mullin, Kathleen; Kudrow, David; Croop, Robert; Lovegren, Meghan; Conway, Charles M.; Coric, Vladimir; Lipton, Richard B. Journal: Neurology Issue: Volume 94:Number 20(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Issue 10268 (2nd January 2021) Authors: Croop, Robert; Lipton, Richard B; Kudrow, David; Stock, David A; Kamen, Lisa; Conway, Charles M; Stock, Elyse G; Coric, Vladimir; Goadsby, Peter J Journal: Lancet Issue: Volume 397:Issue 10268(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. (2nd January 2022) Authors: Johnston, Karissa; Popoff, Evan; Deighton, Alison; Dabirvaziri, Parisa; Harris, Linda; Thiry, Alexandra; Croop, Robert; Coric, Vladimir; L'Italien, Gilbert; Moren, James Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 22:Number 1(2022) Page Start: 155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Issue 8 (16th August 2020) Authors: Berman, Gary; Croop, Robert; Kudrow, David; Halverson, Philip; Lovegren, Meghan; Thiry, Alexandra C.; Conway, Charles M.; Coric, Vladimir; Lipton, Richard B. Journal: Headache Issue: Volume 60:Issue 8(2020) Page Start: 1734 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Issue 7 (19th March 2022) Authors: Bhardwaj, Rajinder; Collins, Julie L.; Stringfellow, Joseph; Madonia, Jennifer; Anderson, Matt S.; Finley, Jeri‐anne; Stock, David A.; Coric, Vladimir; Croop, Robert; Bertz, Richard Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 7(2022) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Issue 9 (14th October 2022) Authors: Croop, Robert; Madonia, Jennifer; Stock, David A.; Thiry, Alexandra; Forshaw, Micaela; Murphy, Abigail; Coric, Vladimir; Lipton, Richard B. Journal: Headache Issue: Volume 62:Issue 9(2022) Page Start: 1153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. (31st January 2022) Authors: L'Italien, Gilbert; Popoff, Evan; Johnston, Karissa; McGrath, Donnie; Conway, Charles M; Powell, Lauren; Harris, Linda; Kowalczyk, Nicole; Croop, Robert; Coric, Vladimir Journal: Cephalalgia reports Issue: Volume 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗